Empirical Finance LLC Sells 578 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Empirical Finance LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 42,746 shares of the biopharmaceutical company’s stock after selling 578 shares during the period. Empirical Finance LLC’s holdings in Gilead Sciences were worth $3,948,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. nVerses Capital LLC purchased a new stake in Gilead Sciences during the 3rd quarter valued at $25,000. HHM Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares during the last quarter. Valued Wealth Advisors LLC boosted its stake in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares during the period. YANKCOM Partnership purchased a new stake in Gilead Sciences in the 4th quarter worth about $28,000. Finally, Decker Retirement Planning Inc. purchased a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $29,000. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the transaction, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 142,180 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 572,824 shares of company stock valued at $53,611,715. 0.16% of the stock is owned by company insiders.

Gilead Sciences Stock Performance

GILD opened at $96.04 on Friday. The firm has a market capitalization of $119.69 billion, a PE ratio of 1,067.11, a P/E/G ratio of 1.25 and a beta of 0.18. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $100.51. The firm has a 50 day moving average of $93.04 and a two-hundred day moving average of $86.65. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm’s revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the company earned $2.29 earnings per share. On average, analysts anticipate that Gilead Sciences, Inc. will post 4.35 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on GILD shares. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Thursday, November 7th. Wolfe Research assumed coverage on shares of Gilead Sciences in a research report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price objective for the company. Piper Sandler boosted their price target on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. lifted their target price on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Finally, Wells Fargo & Company increased their price target on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.